The U.S. Food and Drug Administration has approved Horizant Extended Release Tablets (gabapentin enacarbil) as a daily treatment for moderate-to-severe restless legs syndrome (RLS). Read more at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm250188.htm.
FDA approves new daily treatment for RLS
Share
Get your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.
NurseLine Newsletter
*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.
